Dr.NateNeph said:MASHdoc_SA said: ...but the FDA says semaglutide...
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.
Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
Following on from DanielChem_CHI — and this may be the naive question:
How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?
lucas_SP_BR said:Agreed, and ALT falling is not the same as fibrosis improving.
I read this differently from lucas_SP_BR, on substance rather than tone. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardslucas_SP_BR said:Agreed, and ALT falling is not the same as fibrosis improving.
Fair, and it stops being fair at the extremes. The middle of the range is well understood; the ends are where the honest answer is that nobody knows.
Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Thread quality here is what the rules are for. Keep it up.